Strategic move expands biologicals capabilities, reinforces innovation pipeline, and positions India as a key hub for animal health growth

Virbac has strengthened its global biologicals and vaccines business through the integration of Indian poultry vaccine specialist Globion, which will now operate as Virbac Biologicals Pvt. Ltd., marking a significant expansion of the company’s animal health platform across India, the Middle East and Africa.

The transition represents a major strategic milestone for the France-headquartered animal health company as it seeks to accelerate growth in the high-value biologicals segment, particularly in poultry health. By combining Globion’s expertise in vaccine development and manufacturing with Virbac’s global research, commercial, and distribution capabilities, the company aims to enhance its ability to deliver advanced disease-prevention solutions to veterinarians, poultry producers, and livestock stakeholders.

The integration comes at a time when demand for preventive animal healthcare is rising globally, driven by increasing concerns over disease outbreaks, food security, antimicrobial stewardship, and the need to improve productivity across livestock and poultry production systems. Vaccines and biologicals are increasingly viewed as critical tools for supporting sustainable animal agriculture while reducing dependence on therapeutic interventions.

Virbac said the newly established Virbac Biologicals will become a key pillar within its broader animal health portfolio, strengthening capabilities in vaccine innovation, manufacturing excellence, and scientific research. The company plans to leverage the platform to develop next-generation biological solutions that address evolving disease challenges while supporting productivity and animal welfare outcomes.

The move also reinforces India’s growing importance in the global animal health ecosystem. With one of the world’s largest poultry industries and increasing investments in veterinary healthcare, India is emerging as a strategic center for vaccine development, manufacturing, and innovation. Industry observers note that the integration reflects a broader trend of consolidation and investment in animal health biologicals, as companies seek to expand preventive healthcare portfolios amid rising demand for safe, sustainable, and science-driven livestock production systems.

Going forward, Virbac Biologicals is expected to focus on expanding research capabilities, strengthening manufacturing infrastructure, and accelerating the development of innovative vaccines and biological products tailored to the needs of poultry and livestock producers across emerging and developed markets alike. The integration underscores Virbac’s long-term commitment to advancing animal health through science-led innovation while strengthening its position in one of the fastest-growing segments of the global veterinary healthcare industry.